S&P 500   3,892.64 (-0.21%)
DOW   31,218.13 (-0.11%)
QQQ   285.45 (-1.43%)
AAPL   135.87 (-1.08%)
MSFT   248.99 (-1.64%)
FB   192.38 (+0.57%)
GOOGL   2,152.80 (-2.49%)
AMZN   2,136.79 (-0.45%)
TSLA   650.50 (-8.31%)
NVDA   163.64 (-4.44%)
BABA   86.89 (-0.91%)
NIO   16.21 (-2.70%)
AMD   91.86 (-4.98%)
CGC   5.45 (-7.16%)
MU   68.05 (-1.95%)
T   20.28 (+0.35%)
GE   74.74 (-1.32%)
F   12.40 (-3.50%)
DIS   101.73 (-1.37%)
AMC   11.78 (-9.94%)
PFE   52.10 (+2.86%)
PYPL   79.29 (-2.45%)
NFLX   184.03 (+0.30%)
S&P 500   3,892.64 (-0.21%)
DOW   31,218.13 (-0.11%)
QQQ   285.45 (-1.43%)
AAPL   135.87 (-1.08%)
MSFT   248.99 (-1.64%)
FB   192.38 (+0.57%)
GOOGL   2,152.80 (-2.49%)
AMZN   2,136.79 (-0.45%)
TSLA   650.50 (-8.31%)
NVDA   163.64 (-4.44%)
BABA   86.89 (-0.91%)
NIO   16.21 (-2.70%)
AMD   91.86 (-4.98%)
CGC   5.45 (-7.16%)
MU   68.05 (-1.95%)
T   20.28 (+0.35%)
GE   74.74 (-1.32%)
F   12.40 (-3.50%)
DIS   101.73 (-1.37%)
AMC   11.78 (-9.94%)
PFE   52.10 (+2.86%)
PYPL   79.29 (-2.45%)
NFLX   184.03 (+0.30%)
S&P 500   3,892.64 (-0.21%)
DOW   31,218.13 (-0.11%)
QQQ   285.45 (-1.43%)
AAPL   135.87 (-1.08%)
MSFT   248.99 (-1.64%)
FB   192.38 (+0.57%)
GOOGL   2,152.80 (-2.49%)
AMZN   2,136.79 (-0.45%)
TSLA   650.50 (-8.31%)
NVDA   163.64 (-4.44%)
BABA   86.89 (-0.91%)
NIO   16.21 (-2.70%)
AMD   91.86 (-4.98%)
CGC   5.45 (-7.16%)
MU   68.05 (-1.95%)
T   20.28 (+0.35%)
GE   74.74 (-1.32%)
F   12.40 (-3.50%)
DIS   101.73 (-1.37%)
AMC   11.78 (-9.94%)
PFE   52.10 (+2.86%)
PYPL   79.29 (-2.45%)
NFLX   184.03 (+0.30%)
S&P 500   3,892.64 (-0.21%)
DOW   31,218.13 (-0.11%)
QQQ   285.45 (-1.43%)
AAPL   135.87 (-1.08%)
MSFT   248.99 (-1.64%)
FB   192.38 (+0.57%)
GOOGL   2,152.80 (-2.49%)
AMZN   2,136.79 (-0.45%)
TSLA   650.50 (-8.31%)
NVDA   163.64 (-4.44%)
BABA   86.89 (-0.91%)
NIO   16.21 (-2.70%)
AMD   91.86 (-4.98%)
CGC   5.45 (-7.16%)
MU   68.05 (-1.95%)
T   20.28 (+0.35%)
GE   74.74 (-1.32%)
F   12.40 (-3.50%)
DIS   101.73 (-1.37%)
AMC   11.78 (-9.94%)
PFE   52.10 (+2.86%)
PYPL   79.29 (-2.45%)
NFLX   184.03 (+0.30%)
NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Forecast, Price & News

$13.19
-0.08 (-0.60%)
(As of 05/20/2022 03:38 PM ET)
Add
Compare
Today's Range
$12.75
$13.94
50-Day Range
$10.26
$23.59
52-Week Range
$9.85
$43.26
Volume
4,921 shs
Average Volume
447,373 shs
Market Capitalization
$390.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
30 days | 90 days | 365 days | Advanced Chart
Receive RAPT News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Therapeutics logo

About RAPT Therapeutics

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAPT
Fax
N/A
Employees
81
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.81 million
Book Value
$5.66 per share

Profitability

Net Income
$-69.20 million
Net Margins
-2,263.55%
Pretax Margin
-2,263.55%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,162,000
Market Cap
$390.95 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/20/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

136th out of 1,420 stocks

Pharmaceutical Preparations Industry

54th out of 679 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -













RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions

Is RAPT Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT Therapeutics stock.
View analyst ratings for RAPT Therapeutics
or view top-rated stocks.

When is RAPT Therapeutics' next earnings date?

RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for RAPT Therapeutics
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) posted its quarterly earnings results on Wednesday, May, 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.01. RAPT Therapeutics had a negative trailing twelve-month return on equity of 37.82% and a negative net margin of 2,263.55%.
View RAPT Therapeutics' earnings history
.

What price target have analysts set for RAPT?

7 brokers have issued 1-year target prices for RAPT Therapeutics' shares. Their forecasts range from $30.00 to $72.00. On average, they expect RAPT Therapeutics' share price to reach $54.43 in the next year. This suggests a possible upside of 312.7% from the stock's current price.
View analysts' price targets for RAPT Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are RAPT Therapeutics' key executives?
RAPT Therapeutics' management team includes the following people:
  • Dr. Brian Russell Wong M.D., Ph.D., CEO, Pres & Director (Age 50, Pay $783k)
  • Mr. Rodney K. B. Young, CFO, Principal Accounting Officer & Sec. (Age 59, Pay $561.91k)
  • Dr. William Ho, Chief Medical Officer (Age 56, Pay $564.44k) (LinkedIn Profile)
  • Steve Young Ph.D., VP of Technology
  • Dr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 53) (LinkedIn Profile)
  • Dr. Paul Kassner, Sr. VP of Quantitative & Computational Biology (Age 55)
  • Dr. David Wustrow, Sr. VP of Drug Discovery & Preclinical Devel. (Age 63)
What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics CEO Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among RAPT Therapeutics' employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (4.56%), Vanguard Group Inc. (4.14%), Woodline Partners LP (1.21%), Wellington Management Group LLP (1.02%), Dimensional Fund Advisors LP (0.96%) and Ghost Tree Capital LLC (0.85%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends for RAPT Therapeutics
.

Which major investors are selling RAPT Therapeutics stock?

RAPT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ghost Tree Capital LLC, Citigroup Inc., UBS Group AG, Ensign Peak Advisors Inc, J. Goldman & Co LP, TD Asset Management Inc., and Metropolitan Life Insurance Co NY. Company insiders that have sold RAPT Therapeutics company stock in the last year include Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, and William Ho.
View insider buying and selling activity for RAPT Therapeutics
or view top insider-selling stocks.

Which major investors are buying RAPT Therapeutics stock?

RAPT stock was acquired by a variety of institutional investors in the last quarter, including Woodline Partners LP, Candriam Luxembourg S.C.A., State Street Corp, Dimensional Fund Advisors LP, The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Vanguard Group Inc., and Walleye Capital LLC. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, Rodney Kb Young, and Wendye Robbins.
View insider buying and selling activity for RAPT Therapeutics
or or view top insider-buying stocks.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $13.19.

How much money does RAPT Therapeutics make?

RAPT Therapeutics has a market capitalization of $390.95 million and generates $3.81 million in revenue each year. The company earns $-69.20 million in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does RAPT Therapeutics have?

RAPT Therapeutics employs 81 workers across the globe.

What is RAPT Therapeutics' official website?

The official website for RAPT Therapeutics is www.rapt.com.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 489-9000 or via email at inves[email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.